Portfolio news 0

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, today announced an upcoming oral presentation highlighting the company’s DNA polymerase Theta (Polθ) inhibitor, ART6043, at the European Society for Medical Oncology (ESMO) Congress 2025, taking place between October 17-21, 2025, in Berlin, Germany. ART6043 is a potential first-in-class, selective DNA polymerase domain inhibitor being developed in combination with the PARP inhibitor, olaparib, in patients with cancers that harbor DDR defects.

The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study (NCT05898399), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. This will be the first time that clinical activity for a therapeutic candidate targeting Polθ in humans will be presented.

Details of the oral presentation:

Abstract Title: First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors

Session Category and Title: Mini oral session: Developmental therapeutics

Date: Friday, October 17, 2025

Time: 4:30 – 4:35 PM CEST

Presenter: Dr. Timothy A. Yap, VP and Head of Clinical Development in the Therapeutics Discovery Division at The University of Texas MD Anderson Cancer Center

Location: Heidelberg Auditorium, Hall 6.2

The abstract is available on the ESMO Congress website.

Artios will issue a press release detailing the data presented at the conference following the oral presentation at ESMO.